The Department of Justice will implement two important changes to the Controlled Substance Utilization Review and Evaluation System (CURES), effective April 2022.
The Centers for Medicare & Medicaid Services issued the following updates this week:
The Mental Health Services Oversight & Accountability Commission will host a listening session on Sept. 28 from 3:30 to 5 p.m. (PT) to gather input on the most effective approaches for mental health crisis programs.
The Centers for Medicare & Medicaid Services (CMS) is now posting vaccination rates for skilled-nursing facilities (SNF) to its consumer website Care Compare.
A new report, prepared for the American Hospital Association by Kaufman Hall, projects that hospitals nationwide will lose an estimated $54 billion in net income throughout 2021, even after taking federal relief into account.
The Food and Drug Administration (FDA) has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to allow for a booster dose for certain individuals, including health care workers.
On Sept. 23, the Health Resources and Services Administration (HRSA) released additional details related to the application process for the $25.5 billion distribution announced on Sept. 10. This includes $17 billion for the Phase 4 Provider Relief Fund (PRF) and $8.5 billion from the American Rescue Plan (ARP) for providers who serve rural patients.
CHA has issued a members-only summary, prepared by Health Policy Alternatives, Inc., of the proposed rule detailing the enforcement provisions related to the No Surprises Act
CHA has issued a detailed summary of the federal fiscal year (FFY) 2022 inpatient prospective payment system (IPPS) final rule. The policy and payment provisions in the final rule are effective for FFY 2022 discharges, beginning Oct. 1.
On Sept. 17, a key advisory panel to the U.S. Food and Drug Administration (FDA) issued a limited endorsement of Pfizer vaccine boosters. The FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously to endorse a booster shot of the Pfizer-BioNTech COVID-19 vaccination for two categories of people: those 65 and older, and those […]